Jon Riise

406 total citations
9 papers, 46 citations indexed

About

Jon Riise is a scholar working on Pathology and Forensic Medicine, Molecular Biology and Genetics. According to data from OpenAlex, Jon Riise has authored 9 papers receiving a total of 46 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pathology and Forensic Medicine, 4 papers in Molecular Biology and 4 papers in Genetics. Recurrent topics in Jon Riise's work include Lymphoma Diagnosis and Treatment (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Viral-associated cancers and disorders (2 papers). Jon Riise is often cited by papers focused on Lymphoma Diagnosis and Treatment (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Viral-associated cancers and disorders (2 papers). Jon Riise collaborates with scholars based in Norway, Sweden and Denmark. Jon Riise's co-authors include Dagny Sandnes, Finn Olav Levy, J. B. Osnes, Tor Skomedal, Jan‐Bjørn Osnes, Eirik Qvigstad, Carsten Utoft Niemann, Mats Jerkeman, Karin Fahl Wader and Sirpa Leppä and has published in prestigious journals such as Blood, Cardiovascular Research and European Journal of Pharmacology.

In The Last Decade

Jon Riise

8 papers receiving 46 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jon Riise Norway	5	23	20	17	13	11	9	46
Johan Verschuere Belgium	4	13 0.6×	18 0.9×	7 0.4×	19 1.5×	13 1.2×	6	53
Anil Chhabra United States	2	21 0.9×	20 1.0×	3 0.2×	9 0.7×	9 0.8×	2	69
Laura Horsley United Kingdom	3	5 0.2×	17 0.8×	5 0.3×	13 1.0×	13 1.2×	6	35
Aránzazu Díaz de Bustamante Spain	5	7 0.3×	21 1.1×	16 0.9×	8 0.6×	9 0.8×	10	59
Elena Yureneva United Kingdom	3	7 0.3×	40 2.0×	7 0.4×	3 0.2×	21 1.9×	5	66
Charlotte Gaskell United Kingdom	4	5 0.2×	9 0.5×	7 0.4×	5 0.4×	10 0.9×	8	40
Jonathon P. Orme United Kingdom	5	29 1.3×	58 2.9×	28 1.6×	7 0.5×	6 0.5×	6	101
Adrián Cuevas-Bourdier Spain	3	3 0.1×	21 1.1×	15 0.9×	38 2.9×	23 2.1×	4	63
Tobias Suske Austria	2	7 0.3×	22 1.1×	10 0.6×	3 0.2×	12 1.1×	3	65
Emily R. Whelan United States	4	9 0.4×	20 1.0×	7 0.4×	3 0.2×	23 2.1×	7	50

Countries citing papers authored by Jon Riise

Since Specialization

Citations

This map shows the geographic impact of Jon Riise's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jon Riise with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jon Riise more than expected).

Fields of papers citing papers by Jon Riise

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jon Riise. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jon Riise. The network helps show where Jon Riise may publish in the future.

Co-authorship network of co-authors of Jon Riise

This figure shows the co-authorship network connecting the top 25 collaborators of Jon Riise. A scholar is included among the top collaborators of Jon Riise based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jon Riise. Jon Riise is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Meriranta, Leo, Arne Kolstad, Martin Hutchings, et al.. (2025). Circulating tumor DNA determinants of response and outcome in relapsed/refractory mantle cell lymphoma. Blood Advances. 9(17). 4528–4541. 1 indexed citations

Bentzen, Hans, Jon Riise, Jacob Haaber, et al.. (2025). Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long‐term follow‐up of the Nordic Lymphoma Group MCL6 Philemon trial. HemaSphere. 9(3). e70101–e70101.

Jerkeman, Mats, Karin Fahl Wader, Ingrid Glimelius, et al.. (2024). Acalabrutinib and Rituximab in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma Including a Matched Population-Based External Comparator- the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) Phase II Trial. Blood. 144(Supplement 1). 747–747. 4 indexed citations

Jerkeman, Mats, Arne Kolstad, Martin Hutchings, et al.. (2023). MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial. Blood Advances. 8(2). 407–415. 9 indexed citations

Jerkeman, Mats, Martin Hutchings, Annika Pasanen, et al.. (2022). Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase Ib-II Trial. Blood. 140(Supplement 1). 184–185. 3 indexed citations

Bach, Trond, Jon Riise, Eirik Qvigstad, et al.. (2013). Identification of small molecule NPR-B antagonists by high throughput screening — potential use in heart failure. Naunyn-Schmiedeberg s Archives of Pharmacology. 387(1). 5–14. 5 indexed citations

Riise, Jon, Eirik Qvigstad, Christen P. Dahl, et al.. (2012). Prostaglandin E1 facilitates inotropic effects of 5-HT4 serotonin receptors and β-adrenoceptors in failing human heart. Basic Research in Cardiology. 107(5). 295–295. 2 indexed citations

Riise, Jon, Rizwan I. Hussain, Christen P. Dahl, et al.. (2012). Prostanoid-mediated inotropic responses are attenuated in failing human and rat ventricular myocardium. European Journal of Pharmacology. 686(1-3). 66–73. 10 indexed citations

Riise, Jon, Eirik Qvigstad, Dagny Sandnes, et al.. (2008). Prostanoid F receptors elicit an inotropic effect in rat left ventricle by enhancing myosin light chain phosphorylation. Cardiovascular Research. 80(3). 407–415. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact